What question did this study set out to answer?

To evaluate the clinical efficacy of community-based azithromycin treatment for individuals with suspected COVID-19 at increased risk of adverse outcomes.

March 1, 2021The LancetOpen Access

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

View Full Paper

Ask AI

Bookmark

Authors

CBChristopher ButlerUniversity of Oxford JDJienchi DorwardCentre for the AIDS Programme of Research in South Africa LYLy‐Mee YuUniversity of Oxford

Discussion

Member takes

Implication

Randomized trial evaluates azithromycin for suspected COVID-19 in high-risk outpatients, highlighting the effectiveness of community-based interventions.

Key Points

To evaluate the clinical efficacy of community-based azithromycin treatment for individuals with suspected COVID-19 at increased risk of adverse outcomes.
Randomized, controlled, open-label, adaptive platform trial (PRINCIPLE) conducted in primary care settings across the UK.
Evaluated oral azithromycin versus standard care in community patients with suspected COVID-19 presenting with risk factors for severe disease.
Assessed time to clinical recovery and rates of hospital admission or death associated with outpatient azithromycin use.
Determined the therapeutic utility of azithromycin for routine early intervention against suspected SARS-CoV-2 in community settings.

Cite This Study

Butler et al. (2021) studied this question.

synapsesocial.com/papers/69da1feb0d540cafc58385ec https://doi.org/10.1016/s0140-6736(21)00461-x

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates azithromycin for suspected COVID-19 in high-risk outpatients, highlighting the effectiveness of community-based interventions.

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider